Clal Insurance’s Vertex Pharmaceuticals VRTX Stock Holding History

Clal Insurance’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1M	Buy	2,019 +1,998	+9,514%	+$885K	﹤0.01%	118
2026 Q1	$9K	Sell	21 -4,002	-99%	-$1.87M	﹤0.01%	189
2025 Q4	$1.82M	Sell	4,023 -3	-0.1%	-$1.29K	0.01%	102
2025 Q3	$1.58M	Buy	4,026 +1,506	+60%	+$629K	0.01%	97
2025 Q2	$1.12M	Buy	2,520 +2,465	+4,482%	+$1.14M	0.01%	97
2025 Q1	$27K	Buy	55 +45	+450%	+$21K	﹤0.01%	143
2024 Q4	$4K	Buy	+10	New	+$4.63K	﹤0.01%	158
2023 Q1	–	Sell	-165,240	Closed	-$47.7M	–	160
2022 Q4	$47.7M	Sell	165,240 -47,000	-22%	-$14.3M	0.72%	44
2022 Q3	$61.5M	Sell	212,240 -5,000	-2%	-$1.44M	0.84%	37
2022 Q2	$61.2M	Sell	217,240 -47,760	-18%	-$12.8M	0.81%	41
2022 Q1	$69.2M	Sell	265,000 -216,000	-45%	-$51.3M	0.73%	42
2021 Q4	$106M	Buy	481,000 +323,500	+205%	+$62.9M	1.14%	25
2021 Q3	$28.6M	Buy	157,500 +153,000	+3,400%	+$29.9M	0.33%	85
2021 Q2	$907K	Buy	+4,500	New	+$941K	0.01%	154

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Clal Insurance's VRTX Position: Q2 2026 in Review

Clal Insurance increased its Vertex Pharmaceuticals (VRTX) stake by 9,514% in Q2 2026, buying an estimated $885K and bringing the position to 2,019 shares worth $1M. The position accounts for ﹤0.01% of the portfolio, ranked #118.

Clal Insurance first reported a position in VRTX in Q2 2021 and has held it in 14 quarters since. The position peaked at $106M in Q4 2021. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Clal Insurance held 2,019 shares of Vertex Pharmaceuticals worth $1M as of Q2 2026.
Clal Insurance bought 1,998 Vertex Pharmaceuticals shares in Q2 2026, an estimated $885K.
Vertex Pharmaceuticals made up ﹤0.01% of Clal Insurance's portfolio in Q2 2026, its #118 holding.
Clal Insurance first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 14 quarters since.
Clal Insurance's Vertex Pharmaceuticals position peaked at $106M in Q4 2021.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Clal Insurance's 13F filing for Q2 2026, filed 13 Aug 2026.